What is the current understanding of omega-3 fatty acids in ARDS and ALI based on the available studies?

What is the current understanding of omega-3 fatty acids in ARDS and ALI based on the available studies?

• A. They consistently improve mortality
• B. They improve biomarkers and outcomes in all trials
• C. They are currently not supported by consistent evidence; later studies did not show improvement
• D. They have not been studied

Answer: (C)

Omega-3 fatty acids in ARDS/ALI were explored because EPA and DHA can shift lung inflammation toward a less pro-inflammatory and more resolving profile. In early trials, some studies showed improvements in inflammatory biomarkers and, in a few cases, short-term physiologic markers such as gas exchange or ventilation duration. However, when larger, well-designed trials were conducted, they did not consistently demonstrate a real clinical benefit, especially in hard outcomes like mortality or length of stay. Differences in how the omega-3s were given (enteral versus parenteral formulations), the doses, timing relative to illness onset, and control conditions likely contributed to the mixed results. Overall, the evidence does not support a consistent, clinically meaningful benefit from omega-3 supplementation in ARDS/ALI, with later studies failing to show improvement.

Omega-3 fatty acids in ARDS/ALI were explored because EPA and DHA can shift lung inflammation toward a less pro-inflammatory and more resolving profile. In early trials, some studies showed improvements in inflammatory biomarkers and, in a few cases, short-term physiologic markers such as gas exchange or ventilation duration. However, when larger, well-designed trials were conducted, they did not consistently demonstrate a real clinical benefit, especially in hard outcomes like mortality or length of stay. Differences in how the omega-3s were given (enteral versus parenteral formulations), the doses, timing relative to illness onset, and control conditions likely contributed to the mixed results. Overall, the evidence does not support a consistent, clinically meaningful benefit from omega-3 supplementation in ARDS/ALI, with later studies failing to show improvement.